Figure 1: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 21 Weeks (5 Months) Of Treatment (Galantamine Fig1)
Galantamine Tablet, Film Coated
Product Images NDC 71335-2766
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Galantamine (NDC 71335-2766). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 10: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 13 Weeks Of Treatment (Galantamine Fig10)
Figure 11: Cumulative Percentage Of Patients Completing 13 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 90%, 24 To 32 mg/day 67%. (Galantamine Fig11)
Figure 12 (Galantamine Fig12)
This text appears to be a list of responses on a scale of improvement, from "Markedly Improved" to "Markedly Worse", possibly related to a rating scale called CIBIC-plus. The information also includes a name "T Peosko", numbers, and some symbols like "@".*
Figure 2: Cumulative Percentage Of Patients Completing 21 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 84%, 8 mg/day 77%, 16 mg/day 78% And 24 mg/day 78%. (Galantamine Fig2)
Figure 3: Distribution Of Cibic-plus Ratings At Week 21 (Galantamine Fig3)
This text provides dosage information for Placebo, with different dosages listed in milligrams per day. It also includes a scale to evaluate the level of improvement or change in a medical condition using different categories of improvement/worsening for the CIBIC-plus rating.*
Figure 4: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Galantamine Fig4)
Figure 5 (Galantamine Fig5)
Cumulative Percentage of Patients showing various changes in ADAS-cog score based on the points assigned. The data includes the number of patients at different point intervals and the corresponding changes from baseline. The information is presented in a tabular format, detailing the distribution of patients based on their score changes.*
Figure 6: Distribution Of Cibic-plus Ratings At Week 26 (Galantamine Fig6)
This text provides information on the percentage of patients in different age groups and dosage levels experiencing varying degrees of improvement based on the CIBIC-plus Rating scale. The data includes the number of patients aged 60+ and the dosage received, with categories indicating different levels of improvement or worsening. It appears to be related to a clinical evaluation or research study but may require further context for a complete understanding.*
Figure 7: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Galantamine Fig7)
Figure 8: Cumulative Percentage Of Patients Completing 26 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 87%, 24 mg/day 80%, And 32 mg/day 75%. (Galantamine Fig8)
This text provides information on the Cumulative Percentage of Patients based on their ADAS-cog Change From Baseline score. It compares the results for patients taking placebo at two different doses (24 my/day and 32 my/day) over a span of 10 points, ranging from -5 to 15.*
Figure 9: Distribution Of Cibic-plus Rating At Week 26 (Galantamine Fig9)
This text provides information about the percentage of patients with different levels of improvement in a study. It includes categories such as "Markedly improved," "Moderately improved," "Minimally improved," "No change," "Minimally worse," "Moderately worse," and "Markedly worse" based on their CIBIC-plus Rating. The percentages are displayed for three groups receiving different treatments. The treatment details include "Placebo" and different dosages taken over 24 months/day.*
Chemical Structure (Galantamine Str)
Label (Lbl713352766)
This text provides information about Galantamine Hydrobromide tablets that are equivalent to 4 mg of galantamine base. It includes details of the dosage, storage instructions, and manufacturer information. The tablets are film-coated and come in a package of 60 tablets. The package insert can be accessed via a QR code on the box. The product is manufactured by Aurobindo Pharma and repackaged by Bryant Ranch Prepack, Inc.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
